This is the recording of the regular press briefing of European Medicines Agency on COVID-19 vaccines and therapeutics that took place on 7 April 2021.

00:00 Introduction of speakers and briefing agenda
02:02 Update by Emer Cooke on the safety of AstraZeneca COVID-19 vaccines
06:33 Analysis of blood clots events after the vaccination by AstraZeneca
12:21 Questions from the journalists
12:48 Age/gender correlation with blood clots events after the vaccination by AstraZeneca
14:52 Vaccine hesitancy
15:51 Priorities of different of vaccines for younger women
20:29 Alternative vaccines for 2nd shot (mix and match approach)
22:27 People over 60 at less risk of side effects from AstraZeneca COVID-19 vaccines?
23:37 How the data is evaluated on side effects of vaccines?
25:07 Side effects from vaccines in women under 60
26:36 Example of another drug with similar side effects
29:21 EU guidance on vaccination, availability of different types of vaccines
30:25 Recommendations in different populations
31:52 Use of evidence to assess the safety of vaccines
33:20 Request to AstraZeneca to provide robust data on safety
35:00 AstraZeneca vaccines: side effects in younger women
36:17 Frequency of side-effects from AstraZeneca COVID-19 vaccines
39:53 Investigation on side effects of other vector vaccines
41:31 Intravenous or intramuscular injection
42:22 Is there association of adverse events with COVID-19 vaccine
43:59 Sputnik V COVID-19 vaccine assessment
46:32 Limits of AstraZeneca vaccine to a specific group of population
50:03 Adverse events in Johnson & Johnson vaccine
52:13 The reporting of adverse events
54:18 Use of AstraZeneca in different groups of population

EMA Speakers:
Emer Cook, Executive Director
Sabina Strauss, Chair of Pharmacovigilance Risk Assessment Committee (PRAC)
Peter Arlett, Head of Analytics

EMA Moderator:
Marie-Agnes Heine, Head of Communication

#EMAPresser #COVID19

свернуть